SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-466

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
At least 4-6 years away. The drug is in Phase 2; a large Phase 2b study began in July 2026 with an estimated completion date of October 2031. Phase 3 trials and regulatory review would follow.
Why 3/10
ABBV-466 is a Phase 2-stage asset at a large-cap diversified pharma. The next hard catalyst would be a topline readout from the Phase 2b platform study (M26-266), which began enrolling in July 2026 with no announced readout date. With no dated binary catalyst within ~12 months and the drug representing a tiny fraction of AbbVie's enterprise value, the impact score is low.
Actionable Insight NEUTRAL

The next catalyst for ABBV-466 is further data readouts from the ongoing Phase 2b platform study (M26-266 / NCT07697456), which began enrolling ~2,000 patients in July 2026 across Crohn's disease and ulcerative colitis. No specific topline readout date has been announced. Given AbbVie's diversified pipeline and market cap, ABBV-466 data alone is unlikely to drive a major share-price move in either direction in the near term.

Price Chart

Loading chart...

Executive Summary

ABBV-466 is AbbVie's investigational fixed-dose combination of its blockbuster IL-23 inhibitor Skyrizi (risankizumab) and an anti-alpha-4 beta-7 integrin antibody called trosunilimab, designed for Crohn's disease and ulcerative colitis. On October 19, 2026, AbbVie reported Phase 2a TARGET-CD data showing the combination achieved 30.2% endoscopic remission at Week 12 (primary endpoint) and 40.5% at Week 24, roughly double the rates of either monotherapy, with comparable safety. A larger Phase 2b platform study (M26-266) began enrolling ~2,000 patients in July 2026. For a non-medical investor, ABBV-466 is an early-stage pipeline asset at a $295 billion mega-cap pharma; the data are encouraging but years from potential approval, and the drug represents a tiny fraction of AbbVie's valuation.

How It Works

ABBV-466 is a fixed-dose combination of two antibody drugs. The first, risankizumab (marketed as Skyrizi), blocks IL-23, a protein that drives inflammation in the gut. The second, trosunilimab, blocks alpha-4 beta-7 integrin, a molecule that helps inflammatory immune cells travel to the intestine. By hitting both targets at once, the combination aims to shut down gut inflammation through two separate pathways.

Trial Status

Phase 2a TARGET-CD study (NCT06548542) completed enrollment of 300 patients and reported positive topline data in October 2026. A larger Phase 2b platform study (M26-266 / NCT07697456) began enrolling approximately 2,000 patients in July 2026, evaluating ABBV-466 in both Crohn's disease and ulcerative colitis.

The Two-Sided Case

▲ Bull Case5
ABBV-466 met its primary endpoint in Phase 2a, achieving 30.2% endoscopic remission at Week 12 vs 21.3% for Skyrizi alone and 18.0% for trosunilimab alone, a clinically meaningful additive benefit.
The efficacy gap widened at Week 24 (40.5% vs 22.4% and 20.0%), suggesting the dual mechanism may produce durable responses.
Safety was comparable across arms (SAEs 10.4% vs 9.6% and 9.0%), with no unexpected safety signals from combining the two biologics.
The dual-targeting approach (IL-23 p19 + integrin α4β7) addresses complementary inflammatory pathways, potentially positioning ABBV-466 as a best-in-class therapy for moderate-to-severe Crohn's.
AbbVie is already advancing a large Phase 2b platform study (M26-266) in both Crohn's and ulcerative colitis, signaling strong internal commitment to the program.
▼ Bear Case5
The Phase 2a TARGET-CD study was open-label (no placebo control), which limits the reliability of the efficacy signal and leaves room for confounding.
SAE rates were slightly higher for ABBV-466 (10.4%) vs risankizumab (9.6%) and trosunilimab (9.0%) monotherapy, and combining two biologics could raise long-term safety questions.
ABBV-466 is essentially designed to cannibalize AbbVie's own blockbuster Skyrizi ($10B+ H1 2026 revenue), creating an internal revenue transition risk.
The drug is still in Phase 2; a large Phase 2b study (2,000 patients) only began enrolling in July 2026, meaning regulatory filing is likely years away.
Competition in Crohn's disease is intense, with multiple IL-23 inhibitors (Rinvoq, Entyvio, Stelara biosimilars) and emerging TL1A antibodies.

Upcoming Catalysts

  • Further data readouts from the ongoing Phase 2b platform study M26-266 (no specific date announced)
  • Potential expansion into ulcerative colitis based on the Phase 2b platform design

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 11

Hover a chip for the title
1 news.abbvie.com2 biospace.com3 fiercebiotech.com4 varese-group.com5 finvaulta.com6 prnewswire.com7 fool.com8 econotimes.com9 allsci.com10 abbvieclinicaltrials.com11 clinicaltrials.gov